Micardis

Telmisartan, the active ingredient in Micardis, is a Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Micardis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Micardis (telmisartan) is an angiotensin II receptor blocker used in the management of cardiovascular conditions.

- Hypertension: lowers systolic and diastolic blood pressure in adults. - Essential hypertension: provides long‑term blood pressure control. - Hypertension with diabetes: improves blood pressure management in patients with type 2 diabetes.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Headache: mild to moderate pain in the head region. - Fatigue: unusual tiredness or lack of energy. - Upper respiratory infection: symptoms such as sore throat or nasal congestion. - Back pain: discomfort in the lumbar area. - Cough: occasional dry throat irritation.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat. - Hyperkalemia: elevated potassium levels that may affect heart rhythm. - Renal impairment: sudden decrease in kidney function. - Hepatic injury: signs of liver dysfunction such as jaundice.

Precautions should be observed when initiating or adjusting therapy with Micardis.

- Monitor blood pressure: ensure adequate control and avoid hypotension. - Assess renal function: check serum creatinine and eGFR before and during treatment. - Check electrolytes: especially potassium levels to detect hyperkalemia. - Use caution in severe hepatic impairment: dose adjustment may be required. - Avoid use in pregnancy: safety not established and potential fetal risk. - Store at ambient temperature: keep below 25°C, in the original pack, protected from moisture.

Micardis may interact with several medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal dysfunction. - Potassium‑sparing diuretics: heightened risk of hyperkalemia. - ACE inhibitors: additive effect on potassium and renal function. - NSAIDs: may impair renal function and reduce antihypertensive effect.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive response. - Lithium: increased lithium concentrations, risk of toxicity. - Cyclosporine: elevated cyclosporine levels, requiring dose adjustment.